Dehydroepiandrosterone, obesity and cardiovascular disease risk: A review of human studies

European Journal of Endocrinology

Volumn 151, Issue 1, 2004, Pages 1-14

  Tchernof, André ^a   Labrie, Fernand ^a  

^a LAVAL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANABOLIC AGENT; ANDROGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LIPID; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; PRASTERONE; PRASTERONE SULFATE; TESTOSTERONE;

ABDOMEN; AGING; ANALYTIC METHOD; BODY FAT; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL STUDY; DOSE RESPONSE; DRUG MECHANISM; HEART PROTECTION; HORMONE BLOOD LEVEL; HORMONE SUBSTITUTION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERINSULINEMIA; INSULIN RESISTANCE; LIPID BLOOD LEVEL; LIPID STORAGE; LIPOPROTEIN BLOOD LEVEL; MEDICAL LITERATURE; METHODOLOGY; OBESITY; POPULATION RESEARCH; PREDICTION; PRIORITY JOURNAL; RELIABILITY; REVIEW; RISK ASSESSMENT;

CARDIOVASCULAR DISEASES; DEHYDROEPIANDROSTERONE; HUMANS; OBESITY; RISK FACTORS;

EID: 4344576898     PISSN: 08044643     EISSN: None     Source Type: Journal    
DOI: 10.1530/eje.0.1510001     Document Type: Review

References (151)

1. Labrie F. Intracrinology. Molecular and Cellular Endocrinology 1991 78 C113-C118.
2. Labrie F, Luu-The V, Labrie C, Bélanger A, Simard J, Lin SX et al. Endocrine and intracrine sources of androgens in women: inhibition of breast cancer and other roles of androgens and their precursor dehydroepiandrosterone. Endocrine Reviews 2003 24 152-182.
3. Bélanger A, Candas B, Dupont A, Cusan L, Diamond P, Gomez JL et al. Changes in serum concentrations of conjugated and unconjugated steroids in 40- to 80-year-old men. Journal of Clinical Endocrinology and Metabolism 1994 79 1086-1090.
4. Labrie F, Bélanger A, Cusan L, Gomez JL & Candas B. Marked decline in serum concentrations of adrenal C19 sex steroid precursors and conjugated androgen metabolites during aging. Journal of Clinical Endocrinology and Metabolism 1997 82 2396-2402.
5. Schriock ED, Buffington CK, Hubert GD, Kurtz BR, Kitabachi AE, Buster JE et al. Divergent correlations of circulating dehydroepiandrosterone sulfate and testosterone with insulin levels and insulin receptor binding. Clinical Endocrinology and Metabolism 1988 66 1329-1331.
6. Nestler JE, Barlascini CO, Clore JN & Blackard WG. Dehydroepiandrosterone reduces serum low density lipoprotein levels and body fat but does not alter insulin sensitivity in normal men. Journal of Clinical Endocrinology and Metabolism 1988 66 57-61.
7. Macewen EG & Kurzman ID. Obesity in the dog: role of the adrenal steroid dehydroepiandrosterone (DHEA). Journal of Nutrition 1991 121 S51-S55.
8. Barrett-Connor E, Khaw KT & Yen S. A prospective study of dehydroepiandrosterone sulfate, mortality, and cardiovascular disease. New England Journal of Medicine 1986 315 1519-1524.
9. Schwartz AG, Pashko L & Whitcomb JM. Inhibition of tumor development by dehydroepiandrosterone and related steroids. Toxicologic Pathology 1986 14 357-362.
10. Casson PR, Andersen RN, Herrod HG, Stentz FB, Straughn AB, Abraham GE et al. Oral dehydroepiandrosterone in physiologic doses modulates immune function in postmenopausal women. American Journal of Obstetrics and Gynecology 1993 169 1536-1539.
11. Morales AJ, Nolan JJ, Nelson JC & Yen SSC. Effects of replacement dose of dehydroepiandrosterone in men and women of advancing age. Journal of Clinical Endocrinology and Metabolism 1994 78 1360-1367.
12. Skolnick AA. Scientific verdict still out on DHEA. Journal of the American Medical Association 1996 276 1365-1367.
13. Casson RP & Buster JE. DHEA administration to humans: panacea or palaver? Seminars in Reproductive Endocrinology 1995 13 247-256.
14. Nippolst TB. Dehydroepiandrosterone supplements: bringing sense to sensational claims. Endocrine Practice 1992 4 106-111.
15. Wu FC & Von Eckardstein A. Androgens and coronary artery disease. Endocrine Reviews 2003 24 183-217.
16. Liu PY, Death AK & Handelsman DJ. Androgens and cardiovascular disease. Endocrine Reviews 2003 24 313-340.
17. Muller M, van der Shouw YT, Thijssen JHH & Grobbee DE. Endogenous sex hormones and cardiovascular disease in men. Journal of Clinical Endocrinology and Metabolism 2003 88 5076-5086.
18. Kissebah AH & Krakower GR. Regional adiposity and morbidity. Physiological Reviews 1994 74 761-811.
19. Sims EAH & Berchtold P. Obesity and hypertension: mechanisms and implications for management. Journal of the American Medical Association 1982 247 49-52.
20. Bray GA. Complications of obesity. Annals of Internal Medicine 1985 103 1052-1062.
21. Garrison RJ, Kannel WB, Stokes J III & Castelli WP. Incidence and precursors of hypertension in young adults: the Framingham offspring study. Preventive Medicine 1987 16 235-251.
22. Kissebah AH, Freedman DS & Peiris AN. Health risks of obesity. Medical Clinics of North America 1989 73 111-138.
23. Bray GA, Davidson MB & Drenick EJ. Obesity: a serious symptom. Annals of Internal Medicine 1972 77 797-805.
24. Barrett-Connor E. Obesity, atherosclerosis, and coronary artery disease. Annals of Internal Medicine 1985 103 1010-1019.
25. Manson JE, Willet WC, Stampfer MJ, Colditz GA, Hunter DJ, Hankinson SE et al. Body weight and mortality among women. New England Journal of Medicine 1995 333 677-685.
26. Birmignham CL, Muller JL, Palepu A, Spinelli JJ & Anis AH. The cost of obesity in Canada. The Canadian Medical Association Journal 1999 160 483-488.
27. Flegal KM, Carroll MD, Kuczmarski RJ & Johnson CL. Overweight and obesity in the United States: prevalence and trends, 1960-1994. International Journal of Obesity 1998 22 39-47.
28. Kenchaiah S, Evans JC, Levy D, Wilson PWF, Benjamin EJ, Larson MG et al. Obesity and the risk of heart failure. New England Journal of Medicine 2002 347 305-313.
29. Misra A, Garg A, Abate N, Peshock RM, Stray-Gundersen J & Grundy SM. Relationship of anterior and posterior subcutaneous abdominal fat to insulin sensitivity in nondiabetic men. Obesity Research 1997 5 93-99.
30. Després JP, Moorjani S, Lupien PJ, Tremblay A, Nadeau A & Bouchard C. Regional distribution of body fat, plasma lipoproteins, and cardiovascular disease. Arteriosclerosis 1990 10 497-511.
31. Lapidus L, Bengtsson C, Larsson B, Pennert K, Rybo E & Sjöström L. Distribution of adipose tissue and risk of cardiovascular disease and death: a 12 year follow up of participants in the population study of women in Gothenburg, Sweden. British Medical Journal 1984 289 1261-1263.
32. Larsson B, Svardsudd K, Welin L, Wilhemsen L, Björntorp P & Tibblin G. Abdominal adipose tissue distribution, obesity and risk of cardiovascular disease and death: 13-year follow-up of participants in the study of men born in 1913. British Medical Journal 1984 288 1401-1404.
33. Ohlson LO, Larsson B, Svardsudd K, Welin L, Eriksson H, Wilhemsen L et al. The influence of body fat distribution on the incidence of diabetes mellitus: 13.5 years of follow-up of the participants in the study of men born in 1913. Diabetes 1985 34 1055-1058.
34. Ducimetière P, Richard J & Cambien F. The pattern of subcutaneous fat distribution in middle-aged men and the risk of coronary heart disease: the Paris prospective study. International Journal of Obesity 1986 10 229-240.
35. Donahue RP, Abbot RD, Bloom E, Reed DM & Yano K. Central obesity and coronary heart disease in men. Lancet 1987 i 821-824.
36. Björntorp P. Hazards in subgroups of human obesity. European Journal of Clinical Investigation 1984 14 239-241.
37. Kissebah AH, Vydelingum N, Murray R, Evans DJ, Hartz AJ, Kalkhoff RK et al. Relation of body fat distribution to metabolic complications of obesity. Journal of Clinical Endocrinology and Metabolism 1982 54 254-260.
38. Folsom AR, Kaye SA, Sellers TA, Hong CP, Cerhan JR, Potter JD et al. Body fat distribution and 5-year risk of death in older women. Journal of the American Medical Association 1993 269 483-487.
39. van der Kooy K, Leenen R, Seidell JC, Deurenberg P, Droop A & Bakker CJ. Waist-hip ratio is a poor predictor of changes in visceral fat. American Journal of Clinical Nutrition 1993 57 327-333.
40. Sjöström L, Kvist H, Cederblad A & Tylen U. Determination of total adipose tissue and body fat in women by computed tomography, 40K, and tritium. American Journal of Physiology 1986 250 E736-E745.
41. Després JP, Prud'homme D, Pouliot MC, Tremblay A & Bouchard C. Estimation of deep abdominal adipose-tissue accumulation from simple anthropometric measurements in men. American Journal of Clinical Nutrition 1991 54 471-477.
42. Ferland M, Després JP, Tremblay A, Pinault S, Nadeau A, Moorjani S et al Assessment of adipose tissue distribution by computed axial tomography in obese women: association with body density and anthropometric measurements. British Journal of Nutrition 1989 61 139-148.
43. Després JP, Moorjani S, Ferland M, Tremblay Y, Lupien PJ, Nadeau A et al Adipose tissue distribution and plasma lipoprotein levels in obese women: importance of intra-abdominal fat. Arteriosclerosis 1989 9 203-210.
44. Svendsen OL, Hassager C & Christiansen C. Relationships and independence of body composition, sex hormones, fat distribution and other cardiovascular risk factors in overweight postmenopausal women. International Journal of Obesity 1993 17 459-463.
45. Williams MJ, Hunter GR, Kekes-Szabo T, Snyder S & Treuth MS. Regional fat distribution in women and risk of cardiovascular disease. American Journal of Clinical Nutrition 1997 65 855-860.
46. Wing RR, Matthews KA, Kuller LH, Meilahn EN & Plantinga P. Waist to hip ratio in middle-aged women: associations with behavioral and psychosocial factors and with changes in cardiovascular risk factors. Arteriosclerosis and Thrombosis 1991 11 1250-1257.
47. Campos H, Bailey SM, Gussak LS, Siles X, Ordovas JM & Schaefer EJ. Relations of body habitus, fitness level, and cardiovascular risk factors including lipoproteins in a rural and urban Costa Rican population. Arteriosclerosis and Thrombosis 1991 11 1077-1088.
48. Haarbo J, Hassager C, Schlemmer A & Christiansen C. Influence of smoking, body fat distribution, and alcohol consumption on serum lipids, lipoproteins, and apolipoproteins in early postmenopausal women. Atherosclerosis 1990 84 239-244.
49. Després JP, Nadeau A, Tremblay A, Ferland M, Moorjani S, Lupien PJ et al. Role of deep abdominal fat in the association between regional adipose tissue distribution and glucose tolerance in obese women. Diabetes 1989 38 304-309.
50. Lemieux S, Prud'homme D, Nadeau A, Tremblay A, Bouchard C & Després JP. Seven-year changes in body fat and visceral adipose tissue in women: associations with indexes of plasma glucose-insulin homeostasis. Diabetes Care 1996 19 983-991.
51. Fujioka S, Matsuzawa Y, Tokunaga K, Kano Y, Kobatake T, Keno Y et al. Improvement of glucose and lipid metabolism associated with selective reduction of intra-abdominal visceral fat in premenopausal women with visceral fat obesity. International Journal of Obesity 1991 15 853-859.
52. Barrett-Connor E & Ferrara A. Dehydroepiandrosterone, dehydroepiandrosterone sulfate, obesity, waist-hip ratio, and noninsulin-dependent diabetes in postmenopausal women: the Rancho Bernardo study. Journal of Clinical Endocrinology and Metabolism 1996 81 59-64.
53. de Pergola G, Zamboni M, Sciaraffia M, Turcato E, Pannacciulli N, Armellini F et al. Body fat accumulation is possibly responsible for lower dehydroepiandrosterone circulating levels in premenopausal obese women. International Journal of Obesity 1996 20 1105-1110.
54. de Pergola G, Giagulli VA, Garruti G, Cospite MR, Giorgino F, Cignarelli M et al. Low dehydroepiandrosterone circulating levels in premenopausal obese women with very high body mass index. Metabolism 1991 40 187-190.
55. Field AE, Colditz GA, Willett WC, Longcope C & McKinlay JB. The relation of smoking, age, relative weight, and dietary intake to serum adrenal steroids, sex hormones, and sex hormone-binding globulin in middle-aged men. Journal of Clinical Endocrinology and Metabolism 1994 79 1310-1316.
56. Couillard C, Gagnon J, Bergeron J, Leon AS, Rao DC, Skinner JS et al. Contribution of body fatness and adipose tissue distribution to the age variation in plasma steroid hormone concentrations in men: the HERITAGE family study. Journal of Clinical Endocrinology and Metabolism 2000 85 1026-1031.
57. Tchernof A, Després JP, Bélanger A, Dupont A, Prud'homme D, Moorjani S et al Reduced testosterone and adrenal C19 steroid levels in obese men. Metabolism 1995 44 513-519.
58. Abbassi A, Duthie EH Jr, Sheldahl L, Wilson C, Sasse E, Rudman I et al. Association of dehydroepiandrosterone sulfate, body composition, and physical fitness in independent community-dwelling older men and women. Journal of the American Geriatric Society 1998 46 263-273.
59. Ravaglia G, Ford P, Maioli F, Boschi F, Bernardi M, Pratelli L et al. The relationship of dehydroepiandrosterone sulfate (DHEAS) to endocrine-metabolic parameters and functional status in the oldest-old. Results from an Italian study on healthy free-living over-ninety-year-olds. Journal of Clinical Endocrinology and Metabolism 1996 81 1173-1178.
60. Vermeulen A, Kaufman JM & Giagulli VA. Influence of some biological indexes on sex hormone-binding globulin and androgen levels in aging or obese males. Journal of Clinical Endocrinology and Metabolism 1996 81 1821-1826.
61. Pritchard J, Després JP, Gagnon J, Tchernof A, Nadeau A, Tremblay A et al. Plasma adrenal, gonadal and conjugated steroids before and after long term overfeeding in identical twins. Journal of Clinical Endocrinology and Metabolism 1998 83 3277-3284.
62. Vettor R, de Pergola G, Pagano C, Englaro P, Laudadio E, Giorgino F et al. Gender differences in serum leptin in obese people: relationships with testosterone, body fat distribution and insulin sensitivity. European Journal of Clinical Investigation 1997 27 1016-1024.
63. Herranz L, Megia A, Grande C, Gonzalez Gancedo P & Pallardo F. Dehydroepiandrosterone sulphate, body fat distribution and insulin in obese men. International Journal of Obesity 1995 19 57-60.
64. Haffner SM, Mykkänen L, Valdez RA & Katz MS. Relationship of sex hormones to lipids and lipoproteins in nondiabetic men. Journal of Clinical Endocrinology and Metabolism 1993 77 1610-1615.
65. Haffner SM, Valdez RA, Stern MP & Katz MS. Obesity, body fat distribution and sex hormones in men. International Journal of Obesity 1993 17 643-649.
66. Haffner SM, Valdez RA, Mykkänen L, Stern MP & Katz MS. Decreased testosterone and dehydroepiandrosterone sulfate concentrations are associated with increased insulin and glucose concentrations in nondiabetic men. Metabolism 1994 43 599-603.
67. Haffner SM, Karhapaa P, Mykkänen L & Laakso M. Insulin resistance, body fat distribution, and sex hormones in men. Diabetes 1994 43 212-219.
68. de Pergola G, Triggiani V, Giorgino F, Cospite MR, Garruti G, Cignarelli M et al. The free testosterone to dehydroepiandrosterone sulphate molar ratio as a marker of visceral fat accumulation in premenopausal obese women. International Journal of Obesity 1994 18 659-664.
69. De Simone M, Verrotti A, Lughetti L, Palumbo M, Farello G, Di Cesare E et al. Increased visceral adipose tissue is associated with increased circulating insulin and decreased sex hormone binding globulin levels in massively obese adolescent girls. Journal of Endocrinological Investigation 2001 24 438-444.
70. Williams DP, Boyden TW, Pamenter RW, Lohman TG & Going SB. Relationship of body fat percentage and fat distribution with dehydroepiandrosterone sulfate in premenopausal females. Journal of Clinical Endocrinology and Metabolism 1993 77 80-85.
71. Hautanen A, Mänttäri M, Kupari M, Sarna S, Manninen V, Frick MH et al. Cigarette smoking is associated with elevated adrenal androgen response to adrenocorticotropin. Journal of Steroid Biochemistry and Molecular Biology 1993 46 245-251.
72. Salvini S, Stampfer MJ, Barbieri RL & Hennekens CH. Effects of age, smoking and vitamins on plasma DHEAS levels: a cross-sectional study in men. Journal of Clinical Endocrinology and Metabolism 1992 74 139-143.
73. Evans DJ, Hoffmann RG, Kalkhoff RK & Kissebah AH. Relationship of androgenic activity to body fat topography, fat cell morphology, and metabolic aberrations in premenopausal women. Journal of Clinical Endocrinology and Metabolism 1983 57 304-310.
74. Ivandic A, Prpic-Krizevac I, Sucic M & Juric M. Hyperinsulinemia and sex hormones in healthy premenopausal women: relative contribution of obesity, obesity type, and duration of obesity. Metabolism 1998 47 13-19.
75. Gordon GB, Newitt JA, Shantz LM, Weng DE & Talalay P. Inhibition of the conversion of 3T3 fibroblast clones to adipocytes by dehydroepiandrosterone and related anticarcinogenic steroids. Cancer Research 1986 46 3389-3395.
76. Deslypere JP, Verdonck L & Vermeulen A. Fat tissue: a steroid reservoir and site of steroid metabolism. Journal of Clinical Endocrinology and Metabolism 1985 61 564-570.
77. Fehér T & Bodrogi L. A comparative study of steroid concentrations in human adipose tissue and the peripheral circulation. Clinica et Chimica Acta 1982 126 135-141.
78. Labrie F, Simard J, Luu-The V, Trudel C, Martel C, Labrie C et al. Expression of 3β-hydroxysteroid dehydrogenase/delta5-delta4 isomerase (3β-HSD) and 17β-hydroxysteroid dehydrogenase (17β-HSD) in adipose tissue. International Journal of Obesity 1991 15 91-99.
79. Simpson ER, Merrill JC, Hollub AJ, Graham-Lorence S & Mendelson CR. Regulation of estrogen biosynthesis by human adipose cells. Endocrine Reviews 1989 10 136-148.
80. Price TM & O'Brien SN. Determination of estrogen receptor messenger ribonucleic acid (mRNA) and cytochrome P450 aromatase mRNA levels in adipocytes and adipose stromal cells by competitive polymerase chain reaction amplification. Journal of Clinical Endocrinology and Metabolism 1993 77 1041-1045.
81. Yang K, Khalil MW, Strutt BJ & Killinger DW. 11β-Hydroxysteroid dehydrogenase 1 activity and gene expression in human adipose stromal cells: effects on aromatase activity. Journal of Steroid Biochemistry and Molecular Biology 1997 60 247-253.
82. Bélanger C, Luu-The V, Dupont P & Tchernof A. Adipose tissue intracrinology: potential importance of local androgen/estrogen metabolism in the regulation of adiposity. Hormone and Metabolic Research 2002 34 737-745.
83. Tchernof A, Lévesque E, Beaulieu M, Couture P, Després JP, Hum DW et al. Expression of the androgen metabolizing enzyme UGT2B15 in adipose tissue and relative expression measurement using a competitive RT-PCR method. Clinical Endocrinology 1999 50 637-642.
84. Nestler JE, McClanahan MA, Clore JN & Blackard WG. Insulin inhibits adrenal 17,20-lyase activity in man. Journal of Clinical Endocrinology and Metabolism 1992 74 362-367.
85. Nestler JE, Usiskin KS, Barlascini CO, Welty DF, Clore JN & Blackard WG. Suppression of serum dehydroepiandrosterone sulfate levels by insulin: an evaluation of possible mechanisms. Journal of Clinical Endocrinology and Metabolism 1989 69 1040-1046.
86. Smith S, Ravnikar VA & Barbieri RL. Androgen and insulin response to an oral glucose challenge in hyperandrogenic women. Fertility and Sterility 1987 48 72-77.
87. Falcone T, Finegood DT, Fantus IG & Morris D. Androgen response to endogenous insulin secretion during the frequently sampled intravenous glucose tolerance test in normal and hyperandrogenic women. Journal of Clinical Endocrinology and Metabolism 1990 71 1653-1657.
88. Nestler JE, Clore JN & Blackard WG. Dehydroepiandrosterone: the 'missing link' between hyperinsulinemia and atherosclerosis? FASEB Journal 1992 6 3073-3075.
89. Nestler JE & Kahwash Z. Sex-specific action of insulin to acutely increase the metabolic clearance rate of dehydroepiandrosterone in humans. Journal of Endocrinological Investigation 1994 94 1484-1489.
90. Lavallée B, Provost PR, Nestler JE, Kahwash Z & Bélanger A. Effect of insulin on serum levels of dehydroepiandrosterone metabolites in men. Clinical Endocrinology 1997 46 93-100.
91. Buffington CK, Givens JR & Kitabchi AE. Opposing actions of dehydroepiandrosterone and testosterone on insulin sensitivity. In vivo and in vitro studies of hyperandrogenic females. Diabetes 1991 40 693-700.
92. Tchernof A, Després JP, Dupont A, Bélanger A, Nadeau A, Prud'homme D et al. Relation of steroid hormones to glucose tolerance and plasma insulin levels in men. Diabetes Care 1995 18 292-299.
93. 4) to cardiovascular risk factors in postmenopausal women. American Journal of Epidemiology 1995 142 925-934.
94. Barrett-Connor E. Lower endogenous androgen levels and dyslipidemia in men with non-insulin-dependent diabetes mellitus. Annals of Internal Medicine 1992 117 807-811.
95. Tchernof A, Labrie F, Bélanger A, Bouchard C, Prud'homme D, Moorjani S et al. Relationships between endogenous steroid hormone, sex hormone-binding globulin and lipoprotein levels in men: contribution of visceral obesity, insulin levels and other metabolic variables. Atherosclerosis 1997 133 235-244.
96. Haffner SM, Laakso M, Miettinen H, Mykkänen L, Karhapaa P & Rainwater DL. Low levels of sex-hormone-binding globulin and testosterone are associated with smaller, denser low density lipoprotein in normoglycemic men. Journal of Clinical Endocrinology and Metabolism 1996 81 3697-3701.
97. Rebuffé-Scrive M, Krotkiewski M, Elfverson J & Björntorp P. Muscle and adipose tissue morphology and metabolism in Cushing's syndrome. Journal of Clinical Endocrinology and Metabolism 1988 67 1122-1128.
98. Tchernof A & Després JP. Sex steroid hormones, sex hormone-binding globulin, and obesity in men and women. Hormone and Metabolic Research 2000 32 526-536.
99. 4 in relation to ischemic heart disease mortality in diabetic subjects. The Wisconsin epidemiologic study of diabetic retinopathy. Diabetes Care 1996 19 1045-1050.
100. Hill Golden S, Maguire A, Ding J, Crouse JR, Cauley JA, Zacur H et al. Endogenous postmenopausal hormones and carotid atherosclerosis: a case-control study of the atherosclerosis risk in communities cohort. American Journal of Epidemiology 2002 155 437-445.
101. LaCroix AZ, Yano K & Reed DM. Dehydroepiandrosterone sulfate, incidence of myocardial infarction, and extent of atherosclerosis in men. Circulation 1992 86 1529-1535.
102. Hautanen A, Manttari M, Manninen V, Tenkanen L, Huttunen JK, Frick MH et al. Adrenal androgens and testosterone as coronary risk factors in the Helsinki heart study. Atherosclerosis 1994 105 191-200.
103. Newcomer LM, Manson JE, Barbieri RL, Hennekens CH & Stampfer MJ. Dehydroepiandrosterone sulfate and the risk of myocardial infarction in US male physicians: a prospective study. American Journal of Epidemiology 1994 140 870-875.
104. Contoreggi CS, Blackman MR, Andres R, Muller DC, Lakatta EG, Fleg JL et al. Plasma levels of estradiol, testosterone, and DHEAS do not predict risk of coronary artery disease in men. Journal of Andrology 1990 11 460-470.
105. Legrain S, Berr C, Frenoy N, Gourlet V, Debuire B & Baulieu EE. Dehydroepiandrosterone sulfate in a long-term care aged population. Gerontology 1995 41 343-351.
106. Beer C, Lafont S, Debuire B, Dartigues JF & Beaulieu EE. Relationships of dehydroepiandrosterone sulfate in the elderly with functional, psychological, and mental status, and short-term mortality: a French community-based study. PNAS 1996 93 13410-13415.
107. Tilvis RS, Kähönen M & Härkönen M. Dehydroepiandrosterone sulfate, diseases and mortality in a general aged population. Aging Clinical and Experimental Research 1999 11 30-34.
108. Trivedi DP & Khaw KT. Dehydroepiandrosterone sulfate and mortality in elderly men and women. Journal of Clinical Endocrinology and Metabolism 2001 86 4171-4177.
109. Mazat L, Lafont S, Beer C, Debuire B, Tessier JF & Dartigues JF. Prospective measurements of dehydroepiandrosterone sulfate in a cohort of elderly subjects: relationship to gender, subjective health, smoking habits, and 10-year mortality. PNAS 2001 98 8145-8150.
110. Barrett-Connor E & Khaw KT. Absence of an inverse relation of dehydroepiandrosterone sulfate with cardiovascular mortality in postmenopausal women. New England Journal of Medicine 1987 317 711.
111. Barrett-Connor E & Goodman-Gruen D. Dehydroepiandrosterone sulfate does not predict cardiovascular death in postmenopausal women. The Rancho Bernardo study. Circulation 1995 91 1757-1760.
112. Barrett-Connor E & Goodman-Gruen D. The epidemiology of DHEAS and cardiovascular disease. Annals of the New York Academy of Sciences 1995 774 259-270.
113. Herrington DM. Dehydroepiandrosterone and coronary atherosclerosis. Annals of the New York Academy of Sciences 1995 774 271-280.
114. Ishihara F, Hiramatsu K, Shigematsu S, Aizawa T, Niwa A, Takasu N et al. Role of adrenal androgens in the development of arteriosclerosis as judged by pulse wave velocity and calcification of the aorta. Cardiology 1992 80 332-338.
115. Mitchell LE, Sprecher DL, Borecki IB, Rice T, Laskarzewski PM & Rao DC. Evidence for an association between dehydroepiandrosterone sulfate and nonfatal, premature myocardial infarction in males. Circulation 1994 89 89-93.
116. Zumoff B, Troxler RG, O'Connor J, Rosenfeld RS, Kream J & Levin J. Abnormal hormone levels in men with coronary artery disease. Arteriosclerosis 1982 2 58-67.
117. Bernini GP, Moretti A, Sgrò M, Argenio GF, Barlascini CO, Cristofani R et al. Influence of endogenous androgens on carotid wall in postmenopausal women. Menopause 2001 8 43-50.
118. Slowinska-Srzednicka J, Zgliczynski S, Ciswicka-Sznajderman M, Srzednicki M, Soszynski P, Biernacka M et al. Decreased plasma dehydroepiandrosterone sulfate and dihydroepiandrosterone concentrations in young men after myocardial infarction. Atherosclerosis 1989 79 197-203.
119. Hauner H, Stangl K, Burger K, Busch U, Blomer H & Pfeiffer EF. Sex hormone concentrations in men with angiographically assessed coronary artery disease - relationship to obesity and body fat distribution. Klinische Wochenschrift 1991 69 664-668.
120. Phillips GB, Pinkernell BH & Jing TY. The association of hypotestosteronemia with coronary artery disease in men. Arteriosclerosis and Thrombosis 1994 14 701-706.
121. Jansson JH, Nilsson TK & Johnson O. Von Willebrand factor, tissue plasminogen activator, and dehydroepiandrosterone sulphate predict cardiovascular death in a 10 year follow up of survivors of acute myocardial infarction. Heart 1998 80 334-337.
122. Kiechl S, Willeit J, Bonora E, Schwarz S & Xu Q. No association between dehydroepiandrosterone sulfate and development of atherosclerosis in a prospective population study (Bruneck study). Arteriosclerosis, Thrombosis and Vascular Biology 2000 20 1094-1100.
123. Hak AE, Witteman JCM, de Jong FH, Geerlings MI, Hofman A & Pols HAP. Low levels of endogenous androgens increase the risk of atherosclerosis in elderly men: the Rotterdam study. Journal of Clinical Endocrinology and Metabolism 2002 87 3632-3639.
124. Nafziger AN, Herrington DM & Bush TL. Dehydroepiandrosterone and dehydroepiandrosterone sulfate: their relation to cardiovascular disease. Epidemiologic Reviews 1991 13 267-293.
125. Diamond P, Cusan L, Gomez JL, Bélanger A & Labrie F. Metabolic effect of 12-month percutaneous dehydroepiandrosterone replacement therapy in postmenopausal women. Journal of Endocrinology 1996 150 S43-S50.
126. Mortola JF & Yen SC. The effects of oral dehydroepiandrosterone on endocrine- metabolic parameters in postmenopausal women. Journal of Clinical Endocrinology and Metabolism 1990 71 696-704.
127. Kawano H, Yasue H, Kitagawa A, Hirai N, Yoshida T, Soejima H et al. Dehydroepiandrosterone supplementation improves endothelial function and insulin sensitivity in men. Journal of Clinical Endocrinology and Metabolism 2003 88 3190-3195.
128. Casson PR, Santoro N, Elkind-Hirsch K, Carson SA, Hornsby PJ, Abraham G et al. Postmenopausal dehydroepiandrosterone administration increases free insulin-like growth factor-I and decreases high-density lipoprotein: a six-month trial. Fertility and Sterility 1998 70 107-110.
129. Villareal DT, Holloszy JO & Kohrt WM. Effects of DHEA replacement on bone mineral density and body composition in elderly women and men. Clinical Endocrinology 2000 53 561-568.
130. Arlt W, Callies F, Koehler I, van Vlijmen JC, Fassnacht M, Strasburger CJ et al. Dehydroepiandrosterone supplementation in healthy men with an age-related decline of dehydroepiandrosterone secretion. Journal of Clinical Endocrinology and Metabolism 2001 86 4686-4692.
131. Lovas K, Gebre-Medhin G, Trovik TS, Fougner KJ, Uhlving S, Nedrebo BG et al. Replacement of dehydroepiandrosterone in adrenal failure: no benefit for subjective health status and sexuality in a 9-month, randomized, parallel group clinical trial. Journal of Clinical Endocrinology and Metabolism 2003 88 1112-1118.
132. Flynn MA, Weaver-Osterholtz D, Sharpe-Timms KL, Allen S & Krause G. Dehydroepiandrosterone replacement in aging humans. Journal of Clinical Endocrinology and Metabolism 1999 84 1527-1533.
133. Arlt W, Callies F, van Vlijmen JC, Koehler I, Reincke M, Bidlingmaier M et al. Dehydroepiandrosterone replacement in women with adrenal insuficiency. New England Journal of Medicine 1999 341 1013-1020.
134. Vogiatzi MG, Boeck MA, Vlachopapadopoulou E, El Rashid R & New MI. Dehydroepiandrosterone in morbidly obese adolescents: effects on weight, body composition, lipids, and insulin resistance. Metabolism 1996 45 1011-1015.
135. Barnhart KT, Freeman E, Grisso JA, Rader DJ, Sammel M, Kapoor S et al. The effect of dehydroepiandrosterone supplementation to symptomatic perimenopausal women on serum endocrine profiles, lipid parameters, and health-related quality of life. Journal of Clinical Endocrinology and Metabolism 1999 84 3896-3902.
136. Usiskin KS, Butterworth S, Clore JN, Arad Y, Ginsberg HN, Blackard WG et al. Lack of effect of dehydroepiandrosterone in obese men. International Journal of Obesity 1990 14 457-463.
137. Jedrzejuk D, Medras M, Milewicz A & Demissie M. Dehydroepiandrosterone replacement in healthy men with age-related decline of DHEA-S: effects on fat distribution, insulin sensitivity and lipid metabolism. Aging Male 2003 6 151-156.
138. Percheron G, Hogrel JY, Denot-Ledunois S, Fayet G, Forette F, Baulieu EE et al. Effect of 1-year oral administration of dehydroepiandrosterone to 60- to 80-year-old individuals on muscle function and cross-sectional area: a double-blind placebo-controlled trial. Archives of Internal Medicine 2003 163 720-727.
139. Callies F, Fassnacht M, van Vlijmen JC, Koehler I, Huebler D, Seibel MJ et al, Dehydroepiandrosterone replacement in women with adrenal insufficiency: effects on body composition, serum leptin, bone turnover, and exercise capacity. Journal of Clinical Endocrinology and Metabolism 2001 86 1968-1972.
140. Welle S, Jozefowicz R & Statt M. Failure of dehydroepiandrosterone to influence energy and protein metabolism in humans. Journal of Clinical Endocrinology and Metabolism 1990 71 1259-1264.
141. Ebeling P & Koivisto VA. Physiological importance of dehydroepiandrosterone. Lancet 1994 343 1479-1481
142. Glazer G. Atherogenic effects of anabolic steroids on serum lipid levels. A literature review. Archives of Internal Medicine 1991 151 1925-1933.
143. Mårin P, Holmäng S, Jönsson L, Sjöström L, Kvist H, Holm G et al. The effects of testosterone treatment on body composition and metabolism in middle-aged and obese men. International Journal of Obesity 1992 16 991-997.
144. Mårin P, Odén B & Björntorp P. Assimilation and mobilization of triglycerides in subcutaneous abdominal and femoral adipose tissue in vivo in men: effects of androgens. Journal of Clinical Endocrinology and Metabolism 1995 80 239-243.
145. Mårin P, Lönn L, Andersson B, Odén B, Olbe L, Bengtsson BA & Björntorp P. Assimilation of triglycerides in subcutaneous and intraabdominal adipose tissues in vivo in men: effects of testosterone. Journal of Clinical Endocrinology and Metabolism 1996 81 1018-1022.
146. Mårin P, Holmäng S, Gustafsson C, Jönsson L, Kvist H, Elander A et al. Androgen treatment of abdominally obese men. Obesity Research 1993 1 245-251.
147. Barrett-Connor EL. Testosterone and risk factors for cardiovascular disease in men. Diabète et Métabolisme 1995 21 156-161.
148. Gruenewald DA & Matsumoto AM. Testosterone supplementation therapy for older men: potential benefits and risks. Journal of the American Geriatric Society 2003 51 101-115.
149. Labrie F, Bélanger A, Cusan L & Candas B. Physiological changes in dehydroepiandrosterone are not reflected by serum levels of active androgens and estrogens but of their metabolites: intracrinology. Journal of Clinical Endocrinology and Metabolism 1997 82 2403-2409.
150. Von Eckardstein A & Assmann G. Prevention of coronary heart disease by raising high-density lipoprotein cholesterol? Current Opinion in Lipidology 2000 11 627-637.
151. Maccario M, Mazza E, Ramunni J, Oleandri SE, Procopio M, Gauna G & Ghigo E. Relationships between dehydroepiandrosterone-sulphate and anthropometric, metabolic and hormonal variables in a large cohort of obese women. Clinical Endocrinology 1999 50 595-600.